Antiseptic meeting
This article was originally published in The Tan Sheet
Executive Summary
Anti-infective Drugs Advisory Committee meeting scheduled for May 11 has been cancelled, according to committee hotline. Panelists were to discuss microbiologic endpoints as substitutes for effectiveness in clinical trials intended to address the safety and efficacy of antiseptic health care drug products (1"The Tan Sheet" March 22, 2004, In Brief). FDA has not announced a new date for the meeting...
You may also be interested in...
Topical Corticosteroid Rx-To-OTC Switch Safety To Be Considered By NDAC
The Nonprescription Drugs and Dermatologic & Ophthalmic Drugs (DODAC) advisory committees will discuss guidelines on adequate safety information when considering Rx-to-OTC switches of topical corticosteroids during a March 24 meeting
Antimicrobials review
FDA Anti-Infective Drugs Advisory Committee will discuss microbiologic endpoints as surrogates for efficacy in clinical trials designed to address the safety and efficacy of antiseptic health care drug products, the agency announces. Meeting will be held May 11 at the Holiday Inn in Gaithersburg, Md. Those wishing to make a formal presentation should contact Tara Turner at [email protected], FDA says. Trials could impact OTC antimicrobials. The Cosmetic, Toiletry & Fragrance Association and Soap & Detergent Association have urged the agency to use their proposed test methods to evaluate efficacy of finished topical antimicrobials in the OTC Antiseptic Health Care Final Monograph...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.